[1] Farooq U, Maurer MJ, Thompson CA, et al.  Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy[J]. Br J Haematol, 2017, 179(1): 50-60.   doi: 10.1111/bjh.14813
[2] 胡娜, 吴永港, 肖立志, 等.  18F-FDG PET/CT代谢活性参数及其在淋巴瘤中的应用[J]. 国际放射医学核医学杂志, 2015, 39(4): 342-347.   doi: 10.3760/cma.j.issn.1673-4114.2015.04.015
Hu N, Wu YG, Xiao LZ, et al.  Metabolic parameters of 18F-FDG PET/CT and their application in lymphoma[J]. Int J Radiat Med Nucl Med, 2015, 39(4): 342-347.   doi: 10.3760/cma.j.issn.1673-4114.2015.04.015
[3]

李亚明, 赵晋华. 淋巴瘤PET/CT诊断学[M]. 北京: 人民卫生出版社, 2017.

Li Y M, Zhao J H. PET/CT imaging of lymphoma[M]. Beijing: People's Medical Publishing House, 2017.
[4] 梁颖, 吴宁, 方艳, 等.  18F-FDG PET/CT显像SUVmax、MTV和TLG判断弥漫性大B细胞淋巴瘤的预后价值[J]. 中华核医学与分子影像杂志, 2015, 35(2): 97-101.   doi: 10.3760/cma.j.issn.2095-2848.2015.02.005
Liang Y, Wu N, Fang Y, et al.  Prognostic significance of SUVmax, MTV and TLG on 18F-FDG PET/CT imaging in patients with diffuse large B-cell lymphoma[J]. Chin J Nucl Med Mol Imaging, 2015, 35(2): 97-101.   doi: 10.3760/cma.j.issn.2095-2848.2015.02.005
[5] Okuyucu K, Ozaydın S, Alagoz E, et al.  Prognosis estimation under the light of metabolic tumor parameters on initial FDG-PET/CT in patients with primary extranodal lymphoma[J]. Radiol Oncol, 2016, 50(4): 360-369.   doi: 10.1515/raon-2016-0045
[6] Mikhaeel NG, Smith D, Dunn JT, et al.  Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL[J]. Eur J Nucl Med Mol Imaging, 2016, 43(7): 1209-1219.   doi: 10.1007/s00259-016-3315-7
[7] 丁重阳, 郭喆, 吴宇霖, 等.  18F-FDG PET/CT在局限期小细胞肺癌预后评估中的价值[J]. 中华核医学与分子影像杂志, 2017, 37(11): 694-699.   doi: 10.3760/cma.j.issn.2095-2848.2017.11.005
Ding CY, Guo Z, Wu YS, et al.  Prognostic value of 18F-FDG PET/CT in patients with limited-stage small cell lung cancer[J]. Chin J Nucl Med Mol Imaging, 2017, 37(11): 694-699.   doi: 10.3760/cma.j.issn.2095-2848.2017.11.005
[8] Gallicchio R, Mansueto G, Simeon V, et al.  F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma[J]. Eur J Haematol, 2014, 92(5): 382-389.   doi: 10.1111/ejh.12268
[9] 张玥伟, 范洋, 杨志, 等.  化疗早期及中期18F-FDG PET/CT显像对56例弥漫大B细胞淋巴瘤患者预后的评估价值[J]. 中华血液学杂志, 2015, 36(10): 824-829.   doi: 10.3760/cma.j.issn.0253-2727.2015.10.004
Zhang YW, Fan Y, Yang Z, et al.  The prognosis value of early and interim 18F-FDG-PET/CT scans in patients with diffuse large B-cell lymphoma[J]. Chin J Hematol, 2015, 36(10): 824-829.   doi: 10.3760/cma.j.issn.0253-2727.2015.10.004
[10] Song MK, Yang DH, Lee GW, et al.  High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era[J]. Leuk Res, 2016, 42(1): 1-6.   doi: 10.1016/j.leukres.2016.01.010
[11] Ceriani L, Martelli M, Conconi A, et al.  Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study[J]. Br J Haematol, 2017, 178(4): 588-591.   doi: 10.1111/bjh.14728
[12] Zhou M, Chen Y, Huang H, et al.  Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma[J]. Oncotarget, 2016, 7(50): 83544-83553.   doi: 10.18632/oncotarget.13180
[13] Adams HJ, de Klerk JM, Fijnheer R, et al.  Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma[J]. Eur J Haematol, 2015, 94(6): 532-539.   doi: 10.1111/ejh.12467
[14] Lovinfosse P, Janvary ZL, Coucke P, et al.  FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy[J]. Eur J Nucl Med Mol Imaging, 2016, 43(8): 1453-1460.   doi: 10.1007/s00259-016-3314-8